Abstract
Aim: Evaluation of the impact of the physical exercise in patients with muscular atrophy by analyses of the fibrinogen and thiobarbituric acid reacting substances (TBARS). Cross-sectional study. Convenience sampling: control group (C: n=12) and two groups of wheelchair users: non athletes (NA: n=12) and athletes (A: n=13, professional basketball players). Analyzed biomarkers: fibrinogen and TBARs. Differences were assessed by one-way ANOVA and Newman-Keuls post-hoc. Significance P< 0.05 (IC95). Data are expressed as the mean ± S.E.M.Ethical approval: 462.531 /2013. Fibrinogen values were not different between A (3.67 ± 0.44 mg/dL) and NA (3.44 ± 0.38 mg/dL). On the other hand, it was observed difference between fibrinogen from each group of wheelchair users (A and NA) comparing to C (2.27 ± 0.08 mg/dL) or the standard values of fibrinogen (1.8 mg/dL–3.1 mg/dL): P<0.01and P<0.05, respectively). The TBARS values were not different as compared to the wheel chair users A (3.21 ± 0.24) and NA (3.66 ± 0.27), but they were different (P<0.001) from the C (24.11 ± 1.75). Muscle atrophy of the lower limbs impairs venous return in A and NA. In the absence of difference of both biomarkers between the groups of wheelchair users, it is possible to mention that the upper body exercise does not alter the rheological changes in viscosity, the red cell aggregation (fibrinogen levels), the mitochondrial activity and consequently ROS production (TBARS levels). Therefore, these may be not the only biomarkers to be evaluated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.